Cover Image

A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

Bispecific T-cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL-1 trial and was recently approved by the Food and Drug Administration and the European Medicine...

Full description

Saved in:
Bibliographic Details
Main Authors: Frenking, Jan (Author) , Riedhammer, Christine (Author) , Teipel, Raphael (Author) , Bassermann, Florian (Author) , Besemer, Britta (Author) , Bewarder, Moritz (Author) , Braune, Jan (Author) , Brioli, Annamaria (Author) , Brunner, Franziska (Author) , Dampmann, Maria (Author) , Fenk, Roland (Author) , Gezer, Deniz N. (Author) , Goldman-Mazur, Sarah (Author) , Hanoun, Christine (Author) , Högner, Marion (Author) , Khandanpour, Cyrus (Author) , Kolditz, Katja (Author) , Kos, Igor (Author) , Krönke, Jan (Author) , Kull, Miriam (Author) , Landrin, Valentine (Author) , Leitner, Theo (Author) , Merz, Maximilian (Author) , von Metzler, Ivana (Author) , Michel, Christian S. (Author) , Müller-Tidow, Carsten (Author) , Theurich, Sebastian (Author) , Trautmann-Grill, Karolin (Author) , Wäsch, Ralph (Author) , Zukovs, Romans (Author) , Hänel, Mathias (Author) , Rasche, Leo (Author) , Raab, Marc-Steffen (Author)
Format: Article (Journal)
Language:English
Published: April 2025
In: HemaSphere
Year: 2025, Volume: 9, Issue: 4, Pages: 1-16
ISSN:2572-9241
DOI:10.1002/hem3.70114
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/hem3.70114
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/hem3.70114
Get full text
Author Notes:Jan H. Frenking, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Moritz Bewarder, Jan Braune, Annamaria Brioli, Franziska Brunner, Maria Dampmann, Roland Fenk, Deniz N. Gezer, Sarah Goldman-Mazur, Christine Hanoun, Marion Högner, Cyrus Khandanpour, Katja Kolditz, Igor Kos, Jan Krönke, Miriam Kull, Valentine Landrin, Theo Leitner, Maximilian Merz, Ivana von Metzler, Christian S. Michel, Carsten Müller-Tidow, Sebastian Theurich, Karolin Trautmann-Grill, Ralph Wäsch, Romans Zukovs, Mathias Hänel, Leo Rasche, Marc S. Raab
Description
Summary:Bispecific T-cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL-1 trial and was recently approved by the Food and Drug Administration and the European Medicines Agency. However, treatment under real-world conditions may not represent patient characteristics in clinical trials with restricted enrollment criteria. We performed a retrospective real-world analysis including 138 RRMM patients treated with talquetamab at 21 German centers. Of evaluable patients, 43% had ISS stage III, 37% had extraosseous disease, and 48% had high-risk cytogenetics. After a median of six prior therapy lines, 58% of patients would not have been eligible for MonumenTAL-1. With a median follow-up of 8.2 months, we observed an overall response rate of 65% and a median progression-free survival of 6.4 months (95% confidence interval 5.1-9.0). Prior BTCE exposure, ISS stage III, extraosseous disease, and penta-drug refractory disease were associated with unfavorable outcomes. Grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 5.1% and 1.5% of patients, respectively. In summary, our real-world study confirms the efficacy and safety of talquetamab, despite a high proportion of patient- and disease-related risk factors. These results support its use as bridging or long-term treatment, even in advanced stages.
Item Description:Zuerst veröffentlicht: 17. April 2025
Gesehen am 14.10.2025
Physical Description:Online Resource
ISSN:2572-9241
DOI:10.1002/hem3.70114

Similar Items